varespladib profile

ID Source	ID
PubMed CID	155815
CHEMBL ID	148674
CHEBI ID	189668
SCHEMBL ID	26726
MeSH ID	M0536723

Synonym
(3-aminooxalyl-1-benzyl-2-ethyl-2,3-dihydro-1h-indol-4-yloxy)-acetic acid
(3-aminooxalyl-1-benzyl-2-ethyl-1h-indol-4-yloxy)-acetic acid
2-(3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1h-indol-4-yloxy)acetic acid
bdbm50055366
AKOS015842901
varespladib ,
CHEMBL148674 ,
varepladib
2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetic acid
D08107
varespladib (usan/inn)
172732-68-2
EC-000.2361
FT-0659937
2-[2-ethyl-3-oxamoyl-1-(phenylmethyl)indol-4-yl]oxyethanoic acid
varespladibum
s 5920
ly-315920
({3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1h-indol-4-yl}oxy)acetic acid
CHEBI:189668
2-[[3-(2-amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl]oxy]acetic acid
ly315920
a-001 ,
s-5920 ,
A25228
EX-8676
ly 315920 (varespladib)
2-((3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1h-indol-4-yl)oxy)acetic acid
varespladib (ly315920)
((3-(aminooxoacetyl)-1-benzyl-2-ethyl-1h-indol-4-yl)oxy)acetic acid
acetic acid, ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl)oxy)-,
2q3p98dath ,
varespladib [usan:inn]
unii-2q3p98dath
((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl)oxy)acetate
LY315920 - VARESPLADIB
BCP9000883
HY-13402
BCPP000175
NCGC00346491-01
S1110
varespladib [usan]
varespladib [mi]
((3-(amino(oxo)acetyl)-1-benzyl-2-ethyl-1h-indol-4-yl)oxy)acetic acid
varespladib [who-dd]
acetic acid, ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl)oxy)-
varespladib [inn]
MLS006010414
MLS006010980
smr004701444
SCHEMBL26726
ly 315920\|varespladib\|2-[[3-(2-amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl]oxy]acetic aci
gtpl9657
varespladib methyl (a-002)
varespladib sodium (a-001)
compound 6m [pmid: 8978844]
AC-32931
DTXSID50169378
EX-A153
HMS3654E04
mfcd00944812
J-010846
NCGC00346491-08
SW219559-1
DB11909
AS-16956
BCP01854
Q7915613
AMY19698
BRD-K09711437-001-01-9
SB16690
NCGC00346491-12
HMS3744O03
VRD ,
CCG-268404
NCGC00346491-02
2-{[1-benzyl-3-(carbamoylcarbonyl)-2-ethyl-1h-indol-4-yl]oxy}acetic acid
EN300-144829
Z1721255146

Excerpt	Reference	Relevance
"Varespladib (LY315920) is a potent inhibitor of human group IIA phospholipase A"	( Structural basis of the myotoxic inhibition of the Bothrops pirajai PrTX-I by the synthetic varespladib. Cavalcante, WLG; Fontes, MRM; Fortes-Dias, CL; Lewin, MR; Lomonte, B; Ortolani, PL; Pinto, ÊKR; Salvador, GHM; Soares, AM, 2023)	2.57
"Varespladib is a potent inhibitor of venom secretory phospholipase A"	( The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming. Akpunonu, PD; Bammigatti, C; Bhalla, A; Carter, RW; Gerardo, CJ; Kotehal, SD; Kumar, S; Lewin, MR; Manikath, N; Mukherjee, PP; Platts-Mills, TF; Samuel, SP; Shirazi, FM, 2022)	1.71
"Varespladib (LY315920) is a synthetic molecule clinically tested to block inflammatory cascades of several diseases associated with elevated levels of secreted phospholipase A"	( Structural basis for phospholipase A Bryan-Quirós, W; Fernández, J; Fontes, MRM; Gomes, AAS; Gutiérrez, JM; Lewin, MR; Lomonte, B; Salvador, GHM, 2019)	1.24
"Varespladib appears to be a promissory molecule in the treatment of local effects led by PLA"	( The synthetic varespladib molecule is a multi-functional inhibitor for PLA Borges, RJ; Fontes, MRM; Lewin, MR; Lomonte, B; Salvador, GHM, 2021)	2.42
"Varespladib is a sPLA2 inhibitor shown to be effective in animal models of acute lung injury."	( Surfactant and varespladib co-administration in stimulated rat alveolar macrophages culture. Antonelli, M; Capoluongo, ED; Conti, G; De Luca, D; Fraser, H; Gentile, L; Minucci, A; Perez-Gil, J; Trias, J; Vendittelli, F, 2013)	1.46
"Varespladib is a specifically designed indolic sPLA2 inhibitor, which has shown promising results in animals and adults."	( Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS. Capoluongo, ED; Cogo, PE; Conti, G; De Luca, D; Gentile, L; Giardina, B; Marzano, L; Minucci, A; Piastra, M; Vendittelli, F, 2012)	1.43

Excerpt	Reference	Relevance
"Varespladib was able to inhibit the myotoxic and cytotoxic effects of MjTX-I. "	( The synthetic varespladib molecule is a multi-functional inhibitor for PLA Borges, RJ; Fontes, MRM; Lewin, MR; Lomonte, B; Salvador, GHM, 2021)	2.42
"Varespladib was able to inhibit sPLA2 in the types of neonatal lung injury investigated."	( Varespladib inhibits secretory phospholipase A2 in bronchoalveolar lavage of different types of neonatal lung injury. Capoluongo, E; Conti, G; De Luca, D; Minucci, A; Trias, J; Tripodi, D; Zuppi, C, 2012)	2.54

Excerpt	Reference	Relevance
"Varespladib treatment showed a significant inhibitory effect to snake venom PLA₂, which was estimated by IC"	( Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation. Huang, C; Wang, Y; Xiao, H; Xiong, S; Zhang, D; Zhang, J, 2018)	1.46
"Treatment with varespladib (p=0.019) and varespladib + surfactant (p=0.013), reduced the enzyme activity by approximately 15% from the basal level measured in the untreated cultures."	( Surfactant and varespladib co-administration in stimulated rat alveolar macrophages culture. Antonelli, M; Capoluongo, ED; Conti, G; De Luca, D; Fraser, H; Gentile, L; Minucci, A; Perez-Gil, J; Trias, J; Vendittelli, F, 2013)	1.08

Excerpt	Reference	Relevance
" A-001 is a novel inhibitor of sPLA2 enzymes discovered by structure-based drug design, and A-002 is the orally bioavailable prodrug currently in clinical development."	( Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. Chouinard, ML; Christie, RM; Eacho, PI; Fraser, H; Gould, KE; Hislop, C; Reidy, CA; Rick, HL; Trias, J, 2009)	1.8
" Surprisingly, varespladib and its orally bioavailable prodrug, methyl-varespladib showed high-level secretory PLA2 (sPLA2) inhibition at nanomolar and picomolar concentrations against 28 medically important snake venoms from six continents."	( Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. Bickler, P; Lewin, M; Merkel, J; Samuel, S, 2016)	2.23
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Recently, small, synthetic toxin-specific inhibitors with oral bioavailability used in conjunction with antivenom have been identified as having the potential to greatly improve outcomes after snakebite."	( Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes. Bickler, PE; Carter, RW; Fry, BG; Lewin, MR; Matteo, IA; Rao, S; Samuel, SP, 2022)	2.16

Excerpt	Relevance	Reference
" The primary objectives of this study were to determine whether there was a dose-response relationship between two doses of LY315920Na/S-5920 compared with placebo in the reduction of 28-day all-cause mortality in patients with severe sepsis and to determine whether LY315920Na/S-5920 had an acceptable safety profile."	( Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Abraham, E; Bandi, V; Dmitrienko, A; Farid, N; Forgue, ST; Gervich, D; Jiang, F; Lowry, SF; Macias, W; Naum, C; Schein, RM; Skerjanec, S; Wunderink, R, 2003)	0.32
" However, in a prospectively planned analysis, there was a favorable overall dose-response effect on 28-day all-cause mortality in patients administered LY315920Na/S-5920 within 18 hrs of onset of the first sepsis-induced organ failure."	( Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Abraham, E; Bandi, V; Dmitrienko, A; Farid, N; Forgue, ST; Gervich, D; Jiang, F; Lowry, SF; Macias, W; Naum, C; Schein, RM; Skerjanec, S; Wunderink, R, 2003)	0.32
" The development of varespladib and its oral dosage form, varespladib-methyl, has been accelerated by previous clinical development campaigns to treat non-envenoming conditions related to ulcerative colitis, rheumatoid arthritis, asthma, sepsis, and acute coronary syndrome."	( Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes. Bickler, PE; Carter, RW; Fry, BG; Lewin, MR; Matteo, IA; Rao, S; Samuel, SP, 2022)	2.49

Role	Description
EC 3.1.1.4 (phospholipase A2) inhibitor	An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of phospholipase A2 (EC 3.1.1.4).
anti-inflammatory drug	A substance that reduces or suppresses inflammation.
antidote	Any protective agent counteracting or neutralizing the action of poisons.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
indoles	Any compound containing an indole skeleton.
benzenes	Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
dicarboxylic acid monoamide
monocarboxylic acid	An oxoacid containing a single carboxy group.
primary carboxamide	A carboxamide resulting from the formal condensation of a carboxylic acid with ammonia; formula RC(=O)NH2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	19.7224	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Group 10 secretory phospholipase A2	Homo sapiens (human)	IC50 (µMol)	0.0918	0.0410	0.1038	0.2000	AID1169327; AID1356216; AID1356217; AID1614038; AID1614048; AID1631099; AID264372; AID341251
85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)	IC50 (µMol)	3.0076	0.0460	0.1491	0.6000	AID1614027; AID1614028; AID1614029; AID1614031; AID1614032; AID1614033; AID1614040; AID1614041
Phospholipase A2, major isoenzyme	Sus scrofa (pig)	IC50 (µMol)	0.0480	0.0480	4.1208	8.0000	AID159093; AID1894716
Phospholipase A2	Homo sapiens (human)	IC50 (µMol)	0.3668	0.0030	0.9122	3.9000	AID158796; AID1614038; AID1614048; AID1894715; AID264364; AID341239
Phospholipase A2, membrane associated	Homo sapiens (human)	IC50 (µMol)	0.0527	0.0030	1.0811	8.0000	AID1356218; AID158930; AID158931; AID1614038; AID1614048; AID1631095; AID1894714; AID242401; AID242469; AID264366; AID341241
Phospholipase A2, membrane associated	Mus musculus (house mouse)	IC50 (µMol)	0.0700	0.0300	0.0800	0.1500	AID264367; AID341242
Phospholipase A2 group V	Homo sapiens (human)	IC50 (µMol)	0.2738	0.1000	0.2256	0.5000	AID1356220; AID1614038; AID1614048; AID264370; AID341249
Phospholipase A2 group V	Mus musculus (house mouse)	IC50 (µMol)	0.7500	0.1700	0.5475	0.7500	AID264371; AID341250
Putative inactive group IIC secretory phospholipase A2	Homo sapiens (human)	IC50 (µMol)	0.1225	0.1140	0.1225	0.1310	AID1614038; AID1614048
Group XIIB secretory phospholipase A2-like protein	Homo sapiens (human)	IC50 (µMol)	0.1225	0.1140	0.1225	0.1310	AID1614038; AID1614048
Group XIIA secretory phospholipase A2	Homo sapiens (human)	IC50 (µMol)	0.1225	0.1140	0.1225	0.1310	AID1614038; AID1614048
Group IIF secretory phospholipase A2	Homo sapiens (human)	IC50 (µMol)	0.1250	0.1140	0.1250	0.1310	AID1614038; AID1614048; AID341247
Group 3 secretory phospholipase A2	Homo sapiens (human)	IC50 (µMol)	0.1225	0.1140	0.1225	0.1310	AID1614038; AID1614048
Group IIE secretory phospholipase A2	Homo sapiens (human)	IC50 (µMol)	0.0862	0.0100	0.0710	0.1310	AID1614038; AID1614048; AID264368; AID341245
Group IIE secretory phospholipase A2	Mus musculus (house mouse)	IC50 (µMol)	0.0750	0.0350	0.0617	0.0750	AID264369; AID341246
Group 10 secretory phospholipase A2	Mus musculus (house mouse)	IC50 (µMol)	0.0750	0.0750	0.3500	0.9000	AID264373; AID341252
Group IID secretory phospholipase A2	Homo sapiens (human)	IC50 (µMol)	0.1017	0.0600	0.1017	0.1310	AID1614038; AID1614048; AID341243
Group IID secretory phospholipase A2	Mus musculus (house mouse)	IC50 (µMol)	0.4300	0.4300	0.4300	0.4300	AID341244
Phospholipase A2	Mus musculus (house mouse)	IC50 (µMol)	0.1400	0.1400	0.4267	1.0000	AID264365; AID341240
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Group 10 secretory phospholipase A2	Homo sapiens (human)	XI50	0.0010	0.0001	0.0009	0.0031	AID1614038; AID1614048; AID1614050; AID1614051; AID1614052; AID1614053; AID1614055
85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)	XI50	0.0047	0.0000	0.0016	0.0320	AID1614027; AID1614028; AID1614029; AID1614031; AID1614032; AID1614033; AID1614040; AID1614041
Phospholipase A2	Homo sapiens (human)	XI50	0.0010	0.0000	0.0008	0.0031	AID1614038; AID1614048; AID1614050; AID1614051; AID1614052; AID1614053; AID1614055
Phospholipase A2, membrane associated	Homo sapiens (human)	XI50	0.0010	0.0001	0.0009	0.0031	AID1614038; AID1614048; AID1614050; AID1614051; AID1614052; AID1614053; AID1614055
Phospholipase A2 group V	Homo sapiens (human)	XI50	0.0010	0.0001	0.0009	0.0031	AID1614038; AID1614048; AID1614050; AID1614051; AID1614052; AID1614053; AID1614055
Putative inactive group IIC secretory phospholipase A2	Homo sapiens (human)	XI50	0.0010	0.0001	0.0009	0.0031	AID1614038; AID1614048; AID1614050; AID1614051; AID1614052; AID1614053; AID1614055
Group XIIB secretory phospholipase A2-like protein	Homo sapiens (human)	XI50	0.0010	0.0001	0.0009	0.0031	AID1614038; AID1614048; AID1614050; AID1614051; AID1614052; AID1614053; AID1614055
Group XIIA secretory phospholipase A2	Homo sapiens (human)	XI50	0.0010	0.0001	0.0009	0.0031	AID1614038; AID1614048; AID1614050; AID1614051; AID1614052; AID1614053; AID1614055
Group IIF secretory phospholipase A2	Homo sapiens (human)	XI50	0.0010	0.0001	0.0009	0.0031	AID1614038; AID1614048; AID1614050; AID1614051; AID1614052; AID1614053; AID1614055
Group 3 secretory phospholipase A2	Homo sapiens (human)	XI50	0.0010	0.0001	0.0009	0.0031	AID1614038; AID1614048; AID1614050; AID1614051; AID1614052; AID1614053; AID1614055
Group IIE secretory phospholipase A2	Homo sapiens (human)	XI50	0.0010	0.0001	0.0009	0.0031	AID1614038; AID1614048; AID1614050; AID1614051; AID1614052; AID1614053; AID1614055
Group IID secretory phospholipase A2	Homo sapiens (human)	XI50	0.0010	0.0001	0.0009	0.0031	AID1614038; AID1614048; AID1614050; AID1614051; AID1614052; AID1614053; AID1614055
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
axon guidance	Group 10 secretory phospholipase A2	Homo sapiens (human)
lysophospholipid transport	Group 10 secretory phospholipase A2	Homo sapiens (human)
prostaglandin biosynthetic process	Group 10 secretory phospholipase A2	Homo sapiens (human)
production of molecular mediator involved in inflammatory response	Group 10 secretory phospholipase A2	Homo sapiens (human)
phosphatidylserine metabolic process	Group 10 secretory phospholipase A2	Homo sapiens (human)
fertilization	Group 10 secretory phospholipase A2	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Group 10 secretory phospholipase A2	Homo sapiens (human)
positive regulation of lipid storage	Group 10 secretory phospholipase A2	Homo sapiens (human)
arachidonic acid metabolic process	Group 10 secretory phospholipase A2	Homo sapiens (human)
hair follicle morphogenesis	Group 10 secretory phospholipase A2	Homo sapiens (human)
positive regulation of prostaglandin secretion	Group 10 secretory phospholipase A2	Homo sapiens (human)
low-density lipoprotein particle remodeling	Group 10 secretory phospholipase A2	Homo sapiens (human)
phosphatidylcholine catabolic process	Group 10 secretory phospholipase A2	Homo sapiens (human)
intestinal stem cell homeostasis	Group 10 secretory phospholipase A2	Homo sapiens (human)
macrophage activation	Group 10 secretory phospholipase A2	Homo sapiens (human)
cholesterol homeostasis	Group 10 secretory phospholipase A2	Homo sapiens (human)
regulation of macrophage activation	Group 10 secretory phospholipase A2	Homo sapiens (human)
erythrocyte maturation	Group 10 secretory phospholipase A2	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Group 10 secretory phospholipase A2	Homo sapiens (human)
phosphatidylethanolamine metabolic process	Group 10 secretory phospholipase A2	Homo sapiens (human)
phosphatidylcholine metabolic process	Group 10 secretory phospholipase A2	Homo sapiens (human)
phosphatidylglycerol metabolic process	Group 10 secretory phospholipase A2	Homo sapiens (human)
phosphatidic acid metabolic process	Group 10 secretory phospholipase A2	Homo sapiens (human)
arachidonic acid secretion	Group 10 secretory phospholipase A2	Homo sapiens (human)
negative regulation of inflammatory response	Group 10 secretory phospholipase A2	Homo sapiens (human)
positive regulation of protein metabolic process	Group 10 secretory phospholipase A2	Homo sapiens (human)
defense response to virus	Group 10 secretory phospholipase A2	Homo sapiens (human)
platelet activating factor catabolic process	Group 10 secretory phospholipase A2	Homo sapiens (human)
positive regulation of arachidonic acid secretion	Group 10 secretory phospholipase A2	Homo sapiens (human)
negative regulation of cholesterol efflux	Group 10 secretory phospholipase A2	Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory response	Group 10 secretory phospholipase A2	Homo sapiens (human)
cellular response to leukemia inhibitory factor	Group 10 secretory phospholipase A2	Homo sapiens (human)
positive regulation of acrosome reaction	Group 10 secretory phospholipase A2	Homo sapiens (human)
phospholipid metabolic process	Group 10 secretory phospholipase A2	Homo sapiens (human)
chemotaxis	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
antibacterial humoral response	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
cardiolipin biosynthetic process	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
phosphatidylcholine catabolic process	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulus	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
cardiolipin acyl-chain remodeling	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
phosphatidylethanolamine catabolic process	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
platelet activating factor metabolic process	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
phosphatidic acid metabolic process	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
positive regulation of ceramide biosynthetic process	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
positive regulation of interleukin-8 production	Phospholipase A2	Homo sapiens (human)
positive regulation of MAP kinase activity	Phospholipase A2	Homo sapiens (human)
innate immune response in mucosa	Phospholipase A2	Homo sapiens (human)
neutrophil mediated immunity	Phospholipase A2	Homo sapiens (human)
fatty acid biosynthetic process	Phospholipase A2	Homo sapiens (human)
actin filament organization	Phospholipase A2	Homo sapiens (human)
signal transduction	Phospholipase A2	Homo sapiens (human)
positive regulation of cell population proliferation	Phospholipase A2	Homo sapiens (human)
positive regulation of calcium ion transport into cytosol	Phospholipase A2	Homo sapiens (human)
lipid catabolic process	Phospholipase A2	Homo sapiens (human)
leukotriene biosynthetic process	Phospholipase A2	Homo sapiens (human)
antibacterial humoral response	Phospholipase A2	Homo sapiens (human)
neutrophil chemotaxis	Phospholipase A2	Homo sapiens (human)
activation of phospholipase A2 activity	Phospholipase A2	Homo sapiens (human)
cellular response to insulin stimulus	Phospholipase A2	Homo sapiens (human)
intracellular signal transduction	Phospholipase A2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Phospholipase A2	Homo sapiens (human)
regulation of glucose import	Phospholipase A2	Homo sapiens (human)
phosphatidylcholine metabolic process	Phospholipase A2	Homo sapiens (human)
phosphatidylglycerol metabolic process	Phospholipase A2	Homo sapiens (human)
positive regulation of fibroblast proliferation	Phospholipase A2	Homo sapiens (human)
arachidonic acid secretion	Phospholipase A2	Homo sapiens (human)
positive regulation of protein secretion	Phospholipase A2	Homo sapiens (human)
positive regulation of immune response	Phospholipase A2	Homo sapiens (human)
defense response to Gram-positive bacterium	Phospholipase A2	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Phospholipase A2	Homo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptide	Phospholipase A2	Homo sapiens (human)
positive regulation of podocyte apoptotic process	Phospholipase A2	Homo sapiens (human)
phospholipid metabolic process	Phospholipase A2	Homo sapiens (human)
phospholipid metabolic process	Phospholipase A2, membrane associated	Homo sapiens (human)
inflammatory response	Phospholipase A2, membrane associated	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Phospholipase A2, membrane associated	Homo sapiens (human)
lipid catabolic process	Phospholipase A2, membrane associated	Homo sapiens (human)
killing of cells of another organism	Phospholipase A2, membrane associated	Homo sapiens (human)
low-density lipoprotein particle remodeling	Phospholipase A2, membrane associated	Homo sapiens (human)
intestinal stem cell homeostasis	Phospholipase A2, membrane associated	Homo sapiens (human)
phosphatidylethanolamine metabolic process	Phospholipase A2, membrane associated	Homo sapiens (human)
phosphatidylcholine metabolic process	Phospholipase A2, membrane associated	Homo sapiens (human)
phosphatidic acid metabolic process	Phospholipase A2, membrane associated	Homo sapiens (human)
arachidonic acid secretion	Phospholipase A2, membrane associated	Homo sapiens (human)
positive regulation of inflammatory response	Phospholipase A2, membrane associated	Homo sapiens (human)
defense response to Gram-positive bacterium	Phospholipase A2, membrane associated	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Phospholipase A2, membrane associated	Homo sapiens (human)
regulation of neutrophil activation	Phospholipase A2, membrane associated	Homo sapiens (human)
negative regulation of T cell proliferation	Phospholipase A2, membrane associated	Homo sapiens (human)
fatty acid metabolic process	Phospholipase A2 group V	Homo sapiens (human)
positive regulation of phospholipase activity	Phospholipase A2 group V	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Phospholipase A2 group V	Homo sapiens (human)
leukotriene biosynthetic process	Phospholipase A2 group V	Homo sapiens (human)
low-density lipoprotein particle remodeling	Phospholipase A2 group V	Homo sapiens (human)
phosphatidylcholine catabolic process	Phospholipase A2 group V	Homo sapiens (human)
cardiolipin acyl-chain remodeling	Phospholipase A2 group V	Homo sapiens (human)
positive regulation of phagocytosis	Phospholipase A2 group V	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Phospholipase A2 group V	Homo sapiens (human)
positive regulation of immune complex clearance by monocytes and macrophages	Phospholipase A2 group V	Homo sapiens (human)
phagosome-lysosome fusion	Phospholipase A2 group V	Homo sapiens (human)
positive regulation of opsonization	Phospholipase A2 group V	Homo sapiens (human)
positive regulation of antifungal innate immune response	Phospholipase A2 group V	Homo sapiens (human)
positive regulation of phagosome maturation	Phospholipase A2 group V	Homo sapiens (human)
phospholipid metabolic process	Phospholipase A2 group V	Homo sapiens (human)
negative regulation of T cell proliferation	Phospholipase A2 group V	Homo sapiens (human)
arachidonic acid secretion	Phospholipase A2 group V	Homo sapiens (human)
lipid catabolic process	Putative inactive group IIC secretory phospholipase A2	Homo sapiens (human)
phosphatidylcholine metabolic process	Putative inactive group IIC secretory phospholipase A2	Homo sapiens (human)
arachidonic acid secretion	Putative inactive group IIC secretory phospholipase A2	Homo sapiens (human)
fatty acid biosynthetic process	Putative inactive group IIC secretory phospholipase A2	Homo sapiens (human)
positive regulation of fibroblast proliferation	Putative inactive group IIC secretory phospholipase A2	Homo sapiens (human)
phospholipid metabolic process	Putative inactive group IIC secretory phospholipase A2	Homo sapiens (human)
phospholipid metabolic process	Group XIIB secretory phospholipase A2-like protein	Homo sapiens (human)
lipid catabolic process	Group XIIB secretory phospholipase A2-like protein	Homo sapiens (human)
arachidonic acid secretion	Group XIIB secretory phospholipase A2-like protein	Homo sapiens (human)
triglyceride homeostasis	Group XIIB secretory phospholipase A2-like protein	Homo sapiens (human)
cholesterol homeostasis	Group XIIB secretory phospholipase A2-like protein	Homo sapiens (human)
phospholipid metabolic process	Group XIIA secretory phospholipase A2	Homo sapiens (human)
biological_process	Group XIIA secretory phospholipase A2	Homo sapiens (human)
lipid catabolic process	Group XIIA secretory phospholipase A2	Homo sapiens (human)
arachidonic acid secretion	Group XIIA secretory phospholipase A2	Homo sapiens (human)
lipid catabolic process	Group IIF secretory phospholipase A2	Homo sapiens (human)
arachidonic acid metabolic process	Group IIF secretory phospholipase A2	Homo sapiens (human)
phosphatidylglycerol acyl-chain remodeling	Group IIF secretory phospholipase A2	Homo sapiens (human)
phosphatidylserine acyl-chain remodeling	Group IIF secretory phospholipase A2	Homo sapiens (human)
phosphatidylcholine acyl-chain remodeling	Group IIF secretory phospholipase A2	Homo sapiens (human)
phosphatidylethanolamine acyl-chain remodeling	Group IIF secretory phospholipase A2	Homo sapiens (human)
innate immune response	Group IIF secretory phospholipase A2	Homo sapiens (human)
arachidonic acid secretion	Group IIF secretory phospholipase A2	Homo sapiens (human)
phospholipid metabolic process	Group IIF secretory phospholipase A2	Homo sapiens (human)
negative regulation of T cell proliferation	Group IIF secretory phospholipase A2	Homo sapiens (human)
negative regulation of gene expression	Group 3 secretory phospholipase A2	Homo sapiens (human)
acrosome assembly	Group 3 secretory phospholipase A2	Homo sapiens (human)
production of molecular mediator involved in inflammatory response	Group 3 secretory phospholipase A2	Homo sapiens (human)
phospholipid metabolic process	Group 3 secretory phospholipase A2	Homo sapiens (human)
phosphatidylserine metabolic process	Group 3 secretory phospholipase A2	Homo sapiens (human)
sperm axoneme assembly	Group 3 secretory phospholipase A2	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Group 3 secretory phospholipase A2	Homo sapiens (human)
positive regulation of neuron projection development	Group 3 secretory phospholipase A2	Homo sapiens (human)
lipoxygenase pathway	Group 3 secretory phospholipase A2	Homo sapiens (human)
positive regulation of prostaglandin biosynthetic process	Group 3 secretory phospholipase A2	Homo sapiens (human)
positive regulation of prostaglandin secretion	Group 3 secretory phospholipase A2	Homo sapiens (human)
low-density lipoprotein particle remodeling	Group 3 secretory phospholipase A2	Homo sapiens (human)
high-density lipoprotein particle remodeling	Group 3 secretory phospholipase A2	Homo sapiens (human)
macrophage activation	Group 3 secretory phospholipase A2	Homo sapiens (human)
mast cell degranulation	Group 3 secretory phospholipase A2	Homo sapiens (human)
negative regulation of neuron apoptotic process	Group 3 secretory phospholipase A2	Homo sapiens (human)
phosphatidylethanolamine metabolic process	Group 3 secretory phospholipase A2	Homo sapiens (human)
phosphatidylcholine metabolic process	Group 3 secretory phospholipase A2	Homo sapiens (human)
phosphatidylglycerol metabolic process	Group 3 secretory phospholipase A2	Homo sapiens (human)
phosphatidic acid metabolic process	Group 3 secretory phospholipase A2	Homo sapiens (human)
phosphatidylinositol metabolic process	Group 3 secretory phospholipase A2	Homo sapiens (human)
cell maturation	Group 3 secretory phospholipase A2	Homo sapiens (human)
arachidonic acid secretion	Group 3 secretory phospholipase A2	Homo sapiens (human)
cilium assembly	Group 3 secretory phospholipase A2	Homo sapiens (human)
positive regulation of mast cell differentiation	Group 3 secretory phospholipase A2	Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory response	Group 3 secretory phospholipase A2	Homo sapiens (human)
negative regulation of amyloid-beta clearance	Group 3 secretory phospholipase A2	Homo sapiens (human)
positive regulation of histamine secretion by mast cell	Group 3 secretory phospholipase A2	Homo sapiens (human)
regulation of endocytic recycling	Group 3 secretory phospholipase A2	Homo sapiens (human)
inflammatory response	Group IIE secretory phospholipase A2	Homo sapiens (human)
lipid catabolic process	Group IIE secretory phospholipase A2	Homo sapiens (human)
low-density lipoprotein particle remodeling	Group IIE secretory phospholipase A2	Homo sapiens (human)
phosphatidylcholine metabolic process	Group IIE secretory phospholipase A2	Homo sapiens (human)
phosphatidylglycerol metabolic process	Group IIE secretory phospholipase A2	Homo sapiens (human)
arachidonic acid secretion	Group IIE secretory phospholipase A2	Homo sapiens (human)
phospholipid metabolic process	Group IIE secretory phospholipase A2	Homo sapiens (human)
negative regulation of T cell proliferation	Group IIE secretory phospholipase A2	Homo sapiens (human)
CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation	Group IID secretory phospholipase A2	Homo sapiens (human)
regulation of acute inflammatory response to antigenic stimulus	Group IID secretory phospholipase A2	Homo sapiens (human)
inflammatory response	Group IID secretory phospholipase A2	Homo sapiens (human)
lipid catabolic process	Group IID secretory phospholipase A2	Homo sapiens (human)
phosphatidylethanolamine metabolic process	Group IID secretory phospholipase A2	Homo sapiens (human)
phosphatidylcholine metabolic process	Group IID secretory phospholipase A2	Homo sapiens (human)
phosphatidylglycerol metabolic process	Group IID secretory phospholipase A2	Homo sapiens (human)
arachidonic acid secretion	Group IID secretory phospholipase A2	Homo sapiens (human)
phospholipid metabolic process	Group IID secretory phospholipase A2	Homo sapiens (human)
negative regulation of T cell proliferation	Group IID secretory phospholipase A2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
1-alkyl-2-acetylglycerophosphocholine esterase activity	Group 10 secretory phospholipase A2	Homo sapiens (human)
phospholipase activity	Group 10 secretory phospholipase A2	Homo sapiens (human)
phospholipase A2 activity	Group 10 secretory phospholipase A2	Homo sapiens (human)
protein binding	Group 10 secretory phospholipase A2	Homo sapiens (human)
calcium-dependent phospholipase A2 activity	Group 10 secretory phospholipase A2	Homo sapiens (human)
phospholipid binding	Group 10 secretory phospholipase A2	Homo sapiens (human)
calcium ion binding	Group 10 secretory phospholipase A2	Homo sapiens (human)
1-alkyl-2-acetylglycerophosphocholine esterase activity	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
lysophospholipase activity	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
phospholipase A2 activity	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
protein binding	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
calmodulin binding	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
hydrolase activity	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
serine hydrolase activity	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
identical protein binding	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
calcium-independent phospholipase A2 activity	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
long-chain fatty acyl-CoA hydrolase activity	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
phosphatidyl phospholipase B activity	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
phospholipase A2 activity	Phospholipase A2	Homo sapiens (human)
signaling receptor binding	Phospholipase A2	Homo sapiens (human)
calcium ion binding	Phospholipase A2	Homo sapiens (human)
bile acid binding	Phospholipase A2	Homo sapiens (human)
calcium-dependent phospholipase A2 activity	Phospholipase A2	Homo sapiens (human)
phospholipid binding	Phospholipase A2	Homo sapiens (human)
phospholipase A2 activity	Phospholipase A2, membrane associated	Homo sapiens (human)
phospholipid binding	Phospholipase A2, membrane associated	Homo sapiens (human)
calcium-dependent phospholipase A2 activity	Phospholipase A2, membrane associated	Homo sapiens (human)
calcium ion binding	Phospholipase A2, membrane associated	Homo sapiens (human)
calcium-independent phospholipase A2 activity	Phospholipase A2 group V	Homo sapiens (human)
calcium-dependent phospholipase A2 activity	Phospholipase A2 group V	Homo sapiens (human)
calcium ion binding	Phospholipase A2 group V	Homo sapiens (human)
phospholipid binding	Phospholipase A2 group V	Homo sapiens (human)
calcium-dependent phospholipase A2 activity	Putative inactive group IIC secretory phospholipase A2	Homo sapiens (human)
signaling receptor binding	Putative inactive group IIC secretory phospholipase A2	Homo sapiens (human)
phospholipid binding	Putative inactive group IIC secretory phospholipase A2	Homo sapiens (human)
calcium ion binding	Putative inactive group IIC secretory phospholipase A2	Homo sapiens (human)
phospholipase A2 activity	Group XIIB secretory phospholipase A2-like protein	Homo sapiens (human)
calcium ion binding	Group XIIB secretory phospholipase A2-like protein	Homo sapiens (human)
calcium ion binding	Group XIIA secretory phospholipase A2	Homo sapiens (human)
protein binding	Group XIIA secretory phospholipase A2	Homo sapiens (human)
calcium-dependent phospholipase A2 activity	Group XIIA secretory phospholipase A2	Homo sapiens (human)
phospholipase A2 activity	Group XIIA secretory phospholipase A2	Homo sapiens (human)
phospholipase A2 activity	Group IIF secretory phospholipase A2	Homo sapiens (human)
calcium-dependent phospholipase A2 activity	Group IIF secretory phospholipase A2	Homo sapiens (human)
phospholipid binding	Group IIF secretory phospholipase A2	Homo sapiens (human)
calcium ion binding	Group IIF secretory phospholipase A2	Homo sapiens (human)
metal ion binding	Group 3 secretory phospholipase A2	Homo sapiens (human)
calcium-dependent phospholipase A2 activity	Group 3 secretory phospholipase A2	Homo sapiens (human)
phospholipase A2 activity	Group IIE secretory phospholipase A2	Homo sapiens (human)
calcium ion binding	Group IIE secretory phospholipase A2	Homo sapiens (human)
protein binding	Group IIE secretory phospholipase A2	Homo sapiens (human)
calcium-dependent phospholipase A2 activity	Group IIE secretory phospholipase A2	Homo sapiens (human)
phospholipid binding	Group IIE secretory phospholipase A2	Homo sapiens (human)
phospholipase A2 activity	Group IID secretory phospholipase A2	Homo sapiens (human)
heparin binding	Group IID secretory phospholipase A2	Homo sapiens (human)
heparan sulfate proteoglycan binding	Group IID secretory phospholipase A2	Homo sapiens (human)
calcium-dependent phospholipase A2 activity	Group IID secretory phospholipase A2	Homo sapiens (human)
phospholipid binding	Group IID secretory phospholipase A2	Homo sapiens (human)
calcium ion binding	Group IID secretory phospholipase A2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
acrosomal vesicle	Group 10 secretory phospholipase A2	Homo sapiens (human)
extracellular region	Group 10 secretory phospholipase A2	Homo sapiens (human)
extracellular space	Group 10 secretory phospholipase A2	Homo sapiens (human)
lysosome	Group 10 secretory phospholipase A2	Homo sapiens (human)
extracellular space	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
cytosol	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
plasma membrane	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
microtubule cytoskeleton	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
nuclear speck	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
pseudopodium	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
mitochondrion	85/88 kDa calcium-independent phospholipase A2	Homo sapiens (human)
extracellular region	Phospholipase A2	Homo sapiens (human)
extracellular space	Phospholipase A2	Homo sapiens (human)
cell surface	Phospholipase A2	Homo sapiens (human)
extracellular region	Phospholipase A2, membrane associated	Homo sapiens (human)
extracellular space	Phospholipase A2, membrane associated	Homo sapiens (human)
mitochondrial outer membrane	Phospholipase A2, membrane associated	Homo sapiens (human)
endoplasmic reticulum	Phospholipase A2, membrane associated	Homo sapiens (human)
endoplasmic reticulum membrane	Phospholipase A2, membrane associated	Homo sapiens (human)
plasma membrane	Phospholipase A2, membrane associated	Homo sapiens (human)
secretory granule	Phospholipase A2, membrane associated	Homo sapiens (human)
perinuclear region of cytoplasm	Phospholipase A2, membrane associated	Homo sapiens (human)
extracellular exosome	Phospholipase A2, membrane associated	Homo sapiens (human)
extracellular region	Phospholipase A2 group V	Homo sapiens (human)
Golgi apparatus	Phospholipase A2 group V	Homo sapiens (human)
plasma membrane	Phospholipase A2 group V	Homo sapiens (human)
early phagosome	Phospholipase A2 group V	Homo sapiens (human)
phagolysosome	Phospholipase A2 group V	Homo sapiens (human)
recycling endosome	Phospholipase A2 group V	Homo sapiens (human)
extracellular region	Putative inactive group IIC secretory phospholipase A2	Homo sapiens (human)
extracellular region	Group XIIB secretory phospholipase A2-like protein	Homo sapiens (human)
extracellular region	Group XIIA secretory phospholipase A2	Homo sapiens (human)
cytoplasm	Group XIIA secretory phospholipase A2	Homo sapiens (human)
extracellular region	Group IIF secretory phospholipase A2	Homo sapiens (human)
cytosol	Group IIF secretory phospholipase A2	Homo sapiens (human)
plasma membrane	Group IIF secretory phospholipase A2	Homo sapiens (human)
extracellular region	Group 3 secretory phospholipase A2	Homo sapiens (human)
extracellular space	Group 3 secretory phospholipase A2	Homo sapiens (human)
centriole	Group 3 secretory phospholipase A2	Homo sapiens (human)
plasma membrane	Group 3 secretory phospholipase A2	Homo sapiens (human)
recycling endosome	Group 3 secretory phospholipase A2	Homo sapiens (human)
extracellular region	Group IIE secretory phospholipase A2	Homo sapiens (human)
cytoplasm	Group IIE secretory phospholipase A2	Homo sapiens (human)
extracellular region	Group IID secretory phospholipase A2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (108)

Assay ID	Title	Year	Journal	Article
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID303770	Inhibition of IL-1-beta-induced sPLA2 production in human RASFs at 5 uM by ELISA	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Novel peptide inhibitors of human secretory phospholipase A2 with antiinflammatory activity: solution structure and molecular modeling.
AID1631098	Inhibition of recombinant sPLA2-5 (unknown origin) using 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by colorimetric method	2016	ACS medicinal chemistry letters, Oct-13, Volume: 7, Issue:10	Discovery of AZD2716: A Novel Secreted Phospholipase A
AID1614056	Ratio of XI50 for inhibition of human recombinant sPLA2 using PAPG to XI50 for inhibition of human recombinant sPLA2 using PAPC	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID341242	Inhibition of mouse group2A phospholipase A2 fluorimetric assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID158791	Inhibition of Phospholipase A2 induced contraction of GP lung tissue	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.
AID1614038	Inhibition of human recombinant sPLA2 assessed as reduction in 16:0 LPC formation after 30 mins by HPLC-MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID1614029	Inhibition of human recombinant calcium-independent PLA2 using PAPC as substrate assessed as reduction in free [14C]-AA formation after 30 mins by scintillation counting	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID1614051	Inhibition of human recombinant sPLA2 using PAPC as substrate assessed as reduction in 16:0 LPC formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID1614041	Inhibition of human recombinant calcium-independent PLA2 using PAPG as substrate assessed as reduction in free [14C]-AA formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID264370	Inhibition of human recombinant sPLA2 G5	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding.
AID303772	Inhibition of IL-1-beta-induced MMP1 levels in human RASFs after 1 hr by ELISA	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Novel peptide inhibitors of human secretory phospholipase A2 with antiinflammatory activity: solution structure and molecular modeling.
AID1282014	Inhibition of recombinant human sPLA2 after 30 mins microtiter plate assay	2016	Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7	Emerging targets and new small molecule therapies in Parkinson's disease treatment.
AID1614028	Inhibition of human recombinant calcium-independent PLA2 using PAPC as substrate assessed as reduction in free AA formation after 30 mins by HPLC-MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID264364	Inhibition of human recombinant sPLA2 G1B	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding.
AID158931	Inhibition of human nonpancreatic secretory Phospholipase A2 through chromogenic assay	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.
AID159093	Compound was tested for inhibition of porcine secretory pancreatic PLA2	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.
AID264369	Inhibition of mouse recombinant sPLA2 G2E	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding.
AID1614031	Inhibition of human recombinant calcium-independent PLA2 using PAPS as substrate assessed as reduction in 16:0 LPC formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID303775	Effect on IL-1-beta-stimulated TIMP2 production in human RASFs	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Novel peptide inhibitors of human secretory phospholipase A2 with antiinflammatory activity: solution structure and molecular modeling.
AID1356217	Inhibition of recombinant human sPLA2-10 expressed in Escherichia coli BL21(DE3) using HDL as substrate pretreated for 20 mins followed by substrate addition and measured after 60 mins	2018	ACS medicinal chemistry letters, Jul-12, Volume: 9, Issue:7	Discovery of a Series of Indole-2 Carboxamides as Selective Secreted Phospholipase A
AID1614033	Inhibition of human recombinant calcium-independent PLA2 using PAPE as substrate assessed as reduction in 16:0 LPC formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID341251	Inhibition of human group2X phospholipase A2 fluorimetric assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID228956	Mole fraction of the IC50 concentration of compound divided by the total lipid concentration (1230 uM) in a chromogenic assay	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.
AID76650	Inhibition Arachidonic acid(AA) induced contraction of GP lung tissue	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.
AID1614040	Inhibition of human recombinant calcium-independent PLA2 using PAPG as substrate assessed as reduction in 16:0 LPC formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID1614053	Inhibition of human recombinant sPLA2 using PAPG as substrate assessed as reduction in 16:0 LPG formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID1614032	Inhibition of human recombinant calcium-independent PLA2 using PAPE as substrate assessed as assessed as reduction in free AA formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID341241	Inhibition of human group2A phospholipase A2 fluorimetric assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID303773	Inhibition of IL-1-beta-induced MMP2 levels in human RASFs after 1 hr by ELISA	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Novel peptide inhibitors of human secretory phospholipase A2 with antiinflammatory activity: solution structure and molecular modeling.
AID264372	Inhibition of human recombinant sPLA2 G10	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding.
AID341243	Inhibition of human group2D phospholipase A2 by [3H]oleic acid-labeled Escherichia coli membrane assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID1614050	Inhibition of human recombinant sPLA2 using PAPA as substrate assessed as reduction in 16:0 LPA formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID1631096	Inhibition of sPLA2 in human plasma using 1-Hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphomethanol as substrate preincubated for 10 mins followed by substrate addition measured after 90 mins by fluorescence assay	2016	ACS medicinal chemistry letters, Oct-13, Volume: 7, Issue:10	Discovery of AZD2716: A Novel Secreted Phospholipase A
AID1894716	Inhibition of pig group IB phospholipase A2 incubated for 1 hrs by scintillation counter analysis	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities.
AID341248	Inhibition of mouse group2F phospholipase A2 fluorimetric assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID341244	Inhibition of mouse group2D phospholipase A2 fluorimetric assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID341252	Inhibition of mouse group2X phospholipase A2 fluorimetric assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID1356220	Inhibition of recombinant human sPLA2-5 expressed in Escherichia coli BL21(DE3) using 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine as substrate pretreated for 20 mins followed by substrate addition and measured after 60 mins	2018	ACS medicinal chemistry letters, Jul-12, Volume: 9, Issue:7	Discovery of a Series of Indole-2 Carboxamides as Selective Secreted Phospholipase A
AID1356218	Inhibition of recombinant human sPLA2-2A expressed in Escherichia coli BL21(DE3) using 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine as substrate pretreated for 20 mins followed by substrate addition and measured after 60 mins	2018	ACS medicinal chemistry letters, Jul-12, Volume: 9, Issue:7	Discovery of a Series of Indole-2 Carboxamides as Selective Secreted Phospholipase A
AID242469	Inhibitory concentration against human nonpancreatic secretory phospholipase A2	2005	Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3	Carbocyclic[g]indole inhibitors of human nonpancreatic s-PLA2.
AID1614048	Inhibition of human recombinant sPLA2 assessed as reduction in free FA formation after 30 mins by HPLC-MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID264366	Inhibition of human recombinant sPLA2 G2A	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding.
AID341246	Inhibition of mouse group2E phospholipase A2 fluorimetric assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID341239	Inhibition of human group1B phospholipase A2 fluorimetric assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID341238	Inhibition of human group12A phospholipase A2 at 1.6 uM	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID303774	Inhibition of IL-1-beta-induced MMP9 levels in human RASFs after 1 hr by ELISA	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Novel peptide inhibitors of human secretory phospholipase A2 with antiinflammatory activity: solution structure and molecular modeling.
AID1614052	Inhibition of human recombinant sPLA2 using PAPE as substrate assessed as reduction in 16:0 LPE formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID341249	Inhibition of human group2V phospholipase A2 fluorimetric assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID1631099	Inhibition of recombinant sPLA2-10 (unknown origin) using 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by colorimetric method	2016	ACS medicinal chemistry letters, Oct-13, Volume: 7, Issue:10	Discovery of AZD2716: A Novel Secreted Phospholipase A
AID264368	Inhibition of human recombinant sPLA2 G2E	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding.
AID228957	Mole fraction is the IC50 concentration divided by the total lipid concentration (4000 uM) in DOC/PC assay	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.
AID158930	Inhibition of human nonpancreatic secretory Phospholipase A2 through DOC/PC assay	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.
AID1631097	Unbound fraction in human plasma	2016	ACS medicinal chemistry letters, Oct-13, Volume: 7, Issue:10	Discovery of AZD2716: A Novel Secreted Phospholipase A
AID341250	Inhibition of mouse group2V phospholipase A2 fluorimetric assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID264367	Inhibition of mouse recombinant sPLA2 G2A	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding.
AID1614027	Inhibition of human recombinant calcium-independent PLA2 using PAPC as substrate assessed as reduction in 16:0 LPC formation after 30 mins by HPLC-MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID1631095	Inhibition of recombinant sPLA2-2A (unknown origin) using 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins by colorimetric method	2016	ACS medicinal chemistry letters, Oct-13, Volume: 7, Issue:10	Discovery of AZD2716: A Novel Secreted Phospholipase A
AID264371	Inhibition of mouse recombinant sPLA2 G5	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding.
AID1356216	Inhibition of recombinant human sPLA2-10 expressed in Escherichia coli BL21(DE3) using 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine as substrate pretreated for 20 mins followed by substrate addition and measured after 60 mins	2018	ACS medicinal chemistry letters, Jul-12, Volume: 9, Issue:7	Discovery of a Series of Indole-2 Carboxamides as Selective Secreted Phospholipase A
AID1894715	Inhibition of human group IB phospholipase A2 incubated for 1 hrs by scintillation counter analysis	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities.
AID341247	Inhibition of human group2F phospholipase A2 fluorimetric assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID264373	Inhibition of mouse recombinant sPLA2 G10	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding.
AID1894714	Inhibition of human group IIA phospholipase A2 incubated for 1 hrs by scintillation counter analysis	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities.
AID341240	Inhibition of mouse group1B phospholipase A2 fluorimetric assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID1169327	Inhibition of human sPLA2X using 1,2-bis(heptanoylthio) glycerophosphocholine substrate incubated for 30 mins	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	Discovery of a novel pyrazole series of group X secreted phospholipase A2 inhibitor (sPLA2X) via fragment based virtual screening.
AID1614055	Inhibition of human recombinant sPLA2 using PAPA as substrate assessed as reduction in free FA formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis	2019	Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4	Substrate-Specific Inhibition Constants for Phospholipase A
AID341237	Inhibition of human group3 phospholipase-A2 at 1.6 uM	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID242401	Inhibitory concentration against human nonpancreatic secretory phospholipase A2	2005	Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3	Carbocyclic[g]indole inhibitors of human nonpancreatic s-PLA2.
AID341245	Inhibition of human group2E phospholipase A2 fluorimetric assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
AID303771	Toxicity against human RASF at 1 to 10 uM after 24 hrs	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Novel peptide inhibitors of human secretory phospholipase A2 with antiinflammatory activity: solution structure and molecular modeling.
AID158796	Compound was tested for inhibition of human secretory pancreatic Phospholipase A2	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.
AID264365	Inhibition of mouse recombinant sPLA2 G1B	2006	Journal of medicinal chemistry, May-18, Volume: 49, Issue:10	The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345200	Human sPLA2-2A (Hydrolases)	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides.
AID1345200	Human sPLA2-2A (Hydrolases)	1999	The Journal of pharmacology and experimental therapeutics, Mar, Volume: 288, Issue:3	Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	5 (6.41)	18.2507
2000's	19 (24.36)	29.6817
2010's	28 (35.90)	24.3611
2020's	26 (33.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	11 (13.75%)	5.53%
Reviews	14 (17.50%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	55 (68.75%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
pk 11195 PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine	3.41	1	0	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
ro 5-4864 4'-chlorodiazepam: selectively binds peripheral benzodiazepine receptor	3.41	1	0
aristolochic acid i aristolochic acid I: phospholipase A inhibitor. aristolochic acid A : An aristolochic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.	2.02	1	0	aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound	carcinogenic agent; metabolite; mutagen; nephrotoxin; toxin
clonazepam Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.	3.41	1	0	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	3.41	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
probucol Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).. probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.	3.16	1	0	dithioketal; polyphenol	anti-inflammatory drug; anticholesteremic drug; antilipemic drug; antioxidant; cardiovascular drug
taurocholic acid Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.	2	1	0	amino sulfonic acid; bile acid taurine conjugate	human metabolite
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	6.45	3	3	pyrrole; secondary amine
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	3.16	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
tetrachloroisophthalonitrile tetrachloroisophthalonitrile: structure. chlorothalonil : A dinitrile that is benzene-1,3-dicarbonitrile substituted by four chloro groups. A non-systemic fungicide first introduced in the 1960s, it is used to control a range of diseases in a wide variety of crops.	3.8	1	1	aromatic fungicide; dinitrile; tetrachlorobenzene	antifungal agrochemical
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	14.42	53	9	benzenes; phenyl acetates
pravastatin Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	7.05	1	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
atorvastatin [no description available]	6.45	3	3	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
oxazolidin-2-one Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.	3.16	1	0	carbamate ester; oxazolidinone	metabolite
marimastat marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary. marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide.	2.31	1	0	hydroxamic acid; secondary carboxamide	antineoplastic agent; matrix metalloproteinase inhibitor
fpl 67047xx FPL 67047XX: inhibits phospholipase A2; structure in first source	3.23	1	0
3-octylthio-1,1,1-trifluoro-2-propanone 3-octylthio-1,1,1-trifluoro-2-propanone: a pesticide synergist; inhibits juvenile hormone esterase	2.21	1	0
succinobucol succinobucol: monosuccinic acid ester of probucol; a metabolically stable modification of probucol, an equipotent antioxidant to probucol but is pharmacologically distinct	3.16	1	0	benzoate ester; phenols
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	3.52	2	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	2.91	1	0	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
oleic acid Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.	2.41	2	0	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
prinomastat prinomastat: a diazepine-based hydroxamic acid inhibitor; matrix metalloproteinase (MMP) inhibitor; angiogenesis inhibitor;. prinomastat : A hydroxamic acid that is (3S)-N-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide in which the hydrogen attached to the thiomorpholine nitrogen has been replaced by a [4-(pyridin-4-yloxy)phenyl]sulfonyl group. It is a selective inhibitor with of matrix metalloproteinases (MMPs) 2, 3, 9, 13, and 14.	2.31	1	0	aromatic ether; hydroxamic acid; pyridines; sulfonamide; thiomorpholines	antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor; matrix metalloproteinase inhibitor
tolcapone Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.	3.23	1	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
leukotriene b4 Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.	2	1	0	dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid	human metabolite; mouse metabolite; plant metabolite; vasoconstrictor agent
thromboxane a2 Thromboxane A2: An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).. thromboxane A2 : A thromboxane which is produced by activated platelets and has prothrombotic properties: it stimulates activation of new platelets as well as increases platelet aggregation.	3.32	2	0	epoxy monocarboxylic acid; thromboxanes A	mouse metabolite
dalcetrapib dalcetrapib: inhibits cholesteryl ester transfer protein (CETP)	3.16	1	0	anilide
varespladib methyl varespladib methyl : A methyl ester resulting from the formal condensation of the carboxy group of varespladib with methanol. It is a potential therapy for the treatment of snakebite envenomings in which toxicity depends on the action of PLA2s.	5.93	4	1	aromatic ether; benzenes; indoles; methyl ester; primary carboxamide	anti-inflammatory drug; antidote; EC 3.1.1.4 (phospholipase A2) inhibitor; prodrug
indoxam indoxam: structure in first source	3.61	2	0
darapladib darapladib: a selective lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor, on biomarkers of cardiovascular (CV) risk	6.02	7	0
anacetrapib [no description available]	3.16	1	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2	1	0
d-4f peptide D-4F peptide: an apo A-I mimetic peptide synthesized from D-amino acids; may play a role in reducing inflammatory responses to influenza virus in mice; may also have anti-atherosclerotic properties	3.16	1	0
crotamine crotamine: polypeptide basic toxin isolated from venom of rattlesnake Crotalus durrisus terrificus	2.41	1	0
thromboplastin Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.	2.31	1	0
amg531 [no description available]	3.23	1	0
rvx 208 apabetalone: a bromodomain and extra-terminal domain protein (BET) inhibitor; prevents interactions between BET proteins and acetyl-lysine residues on histone tails to modify epigenetic regulation	3.16	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Rheumatoid Arthritis [description not available]	0	3.82	2	1
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	0	3.82	2	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.04	1	0
Plasmodium falciparum Malaria [description not available]	0	2.1	1	0
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	0	2.1	1	0
Idiopathic Parkinson Disease [description not available]	0	3.04	1	0
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	0	3.04	1	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	4.73	6	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Drug Associated Myopathies [description not available]	0	2.31	1	0
Envenomation, Snakebite [description not available]	0	10.48	19	1
Coagulation Disorders, Blood [description not available]	0	2.41	1	0
Blood Coagulation Disorders Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.	0	2.41	1	0
Amyotonia Congenita [description not available]	0	3.64	2	0
Neuromuscular Diseases A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA.	0	3.64	2	0
Neuromuscular Blockade The intentional interruption of transmission at the NEUROMUSCULAR JUNCTION by external agents, usually neuromuscular blocking agents. It is distinguished from NERVE BLOCK in which nerve conduction (NEURAL CONDUCTION) is interrupted rather than neuromuscular transmission. Neuromuscular blockade is commonly used to produce MUSCLE RELAXATION as an adjunct to anesthesia during surgery and other medical procedures. It is also often used as an experimental manipulation in basic research. It is not strictly speaking anesthesia but is grouped here with anesthetic techniques. The failure of neuromuscular transmission as a result of pathological processes is not included here.	0	8.64	2	0
Acute Kidney Failure [description not available]	0	2.41	1	0
Insect Bites [description not available]	0	2.41	1	0
Insect Bites and Stings Bites and stings inflicted by insects.	0	2.41	1	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	0	2.41	1	0
Tachyarrhythmia [description not available]	0	2.6	1	0
Tachycardia Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.	0	2.6	1	0
Innate Inflammatory Response [description not available]	0	7.42	5	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	7.42	5	1
Encephalopathy, Toxic [description not available]	0	4.04	2	0
Anasarca [description not available]	0	2.17	1	0
Ecchymosis Extravasation of blood into the skin, resulting in a nonelevated, rounded or irregular, blue or purplish patch, larger than a petechia.	0	2.17	1	0
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	0	2.17	1	0
Bleeding [description not available]	0	2.45	2	0
Hemorrhage Bleeding or escape of blood from a vessel.	0	2.45	2	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	0	2.17	1	0
Ulcer A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.	0	2.17	1	0
Cardiac Death [description not available]	0	3.59	1	1
Apoplexy [description not available]	0	5.41	2	2
Angina at Rest [description not available]	0	5.41	2	2
Cardiovascular Stroke [description not available]	0	5.41	2	2
Angina, Unstable Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.	0	5.41	2	2
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	0	5.41	2	2
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	0	5.41	2	2
Acute Coronary Syndrome An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.	0	8.73	6	5
Lung Injury, Acute [description not available]	0	2.08	1	0
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	0	2.08	1	0
Atherogenesis [description not available]	0	13.01	10	1
Atheroma [description not available]	0	2.08	1	0
Elevated Cholesterol [description not available]	0	2.08	1	0
Aortic Diseases Pathological processes involving any part of the AORTA.	0	2.08	1	0
Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.	0	2.08	1	0
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	0	8.01	10	1
Arteriosclerosis, Coronary [description not available]	0	3.01	1	0
Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.	0	3.01	1	0
Coronary Heart Disease [description not available]	0	3.03	1	0
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	1	5.03	1	0
Genetic Predisposition [description not available]	0	2.11	1	0
Hepatitis INFLAMMATION of the LIVER.	0	2.11	1	0
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	0	3.06	1	0
Fusiform Aneurysm Elongated, spindle-shaped dilation in the wall of blood vessels, usually large ARTERIES with ATHEROSCLEROSIS.	0	2.05	1	0
Aneurysm Pathological outpouching or sac-like dilatation in the wall of any blood vessel (ARTERIES or VEINS) or the heart (HEART ANEURYSM). It indicates a thin and weakened area in the wall which may later rupture. Aneurysms are classified by location, etiology, or other characteristics.	0	7.05	1	0
Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.	0	3.37	2	0
Disease Exacerbation [description not available]	0	2.96	1	0
Hyperlipemia [description not available]	0	3.45	1	1
Hyperlipidemias Conditions with excess LIPIDS in the blood.	0	3.45	1	1
Chronic Lung Injury [description not available]	0	2.07	1	0
Aspiration, Meconium [description not available]	0	2.07	1	0
Infantile Respiratory Distress Syndrome [description not available]	0	2.48	2	0
Infections, Respiratory [description not available]	0	2.07	1	0
Hyaline Membrane Disease A respiratory distress syndrome in newborn infants, usually premature infants with insufficient PULMONARY SURFACTANTS. The disease is characterized by the formation of a HYALINE-like membrane lining the terminal respiratory airspaces (PULMONARY ALVEOLI) and subsequent collapse of the lung (PULMONARY ATELECTASIS).	0	2.07	1	0
Meconium Aspiration Syndrome A condition caused by inhalation of MECONIUM into the LUNG of FETUS or NEWBORN, usually due to vigorous respiratory movements during difficult PARTURITION or respiratory system abnormalities. Meconium aspirate may block small airways leading to difficulties in PULMONARY GAS EXCHANGE and ASPIRATION PNEUMONIA.	0	2.07	1	0
Respiratory Distress Syndrome, Newborn A condition of the newborn marked by DYSPNEA with CYANOSIS, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.	0	2.48	2	0
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	0	2.07	1	0
Inflammatory Response Syndrome, Systemic [description not available]	0	4.31	1	1
MODS [description not available]	0	5.28	2	2
Critical Illness A disease or state in which death is possible or imminent.	0	4.31	1	1
Multiple Organ Failure A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.	0	5.28	2	2
Systemic Inflammatory Response Syndrome A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever	0	4.31	1	1
Acute Edematous Pancreatitis [description not available]	0	2.41	2	0
Acute Disease Disease having a short and relatively severe course.	0	2.41	2	0
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	0	2.41	2	0
Asthma, Bronchial [description not available]	0	3.41	1	1
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	0	3.41	1	1
Blood Poisoning [description not available]	0	3.41	1	1
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	0	3.41	1	1
Edema, Pulmonary [description not available]	0	2	1	0
Acute Respiratory Distress Syndrome [description not available]	0	2.69	3	0
Pulmonary Edema Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.	0	2	1	0
Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.	0	2.69	3	0
Injury, Ischemia-Reperfusion [description not available]	0	2	1	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	0	2	1	0

varespladib

Cross-References

Synonyms (79)

Research Excerpts

Overview

Actions

Treatment

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (6)

Protein Targets (21)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (107)

Molecular Functions (20)

Ceullar Components (23)

Bioassays (108)

Research

Studies (78)

Market Indicators

Research Demand Index: 40.81

Study Types

varespladib

Cross-References

Synonyms (79)

Research Excerpts

Overview

Actions

Treatment

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (6)

Protein Targets (21)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (107)

Molecular Functions (20)

Ceullar Components (23)

Bioassays (108)

Research

Studies (78)

Market Indicators

Research Demand Index: 40.81

Study Types

Related Drugs (36)

Related Conditions (88)